PubMed HealthSearch

PubMed · 2513546

Cluster headaches.

Abstract

The patient with cluster headaches will be afflicted with the most severe type of pain that one will encounter. If the physician can do something to help this patient either by symptomatic or, more importantly, prophylactic treatment, he or she will have a most thankful patient. This type of headache is seen most frequently in men, and occurs in a cyclic manner. During an acute cycle, the patient will experience a daily type of pain that may occur many times per day. The pain is usually unilateral and may be accompanied by unilateral lacrimation, conjunctivitis, and clear rhinorrhea. Prednisone is the first treatment we employ. Patients are seen for follow-up approximately twice a week, and their medication is lowered in an appropriate manner, depending on their response to the treatment. Regulation of dosage has to be individualized, and when one reaches the lower dose such as 5 to 10 mg per day, the drug may have to be tapered more slowly, or even maintained at that level for a period of time to prevent further recurrence of symptoms. We frequently will use an intravenous histamine desensitization technique to prevent further attacks. We will give the patient an ergotamine preparation to use for symptomatic relief. As these patients often have headaches during the middle of the night, we will place the patient on a 2-mg ergotamine preparation to take prior to going to bed in the evening. This often works in a prophylactic nature, and prevents the nighttime occurrence of a headache. We believe that following these principles to make the accurate diagnosis and institute the proper therapy will help the practicing otolaryngologist recognize and treat patients suffering from this severe pain.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R E Ryan. 1989. Cluster headaches.. https://pubmed.ncbi.nlm.nih.gov/2513546/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Calcium antagonists as cardioprotective agents.

The potential role that calcium antagonists play toward enhancing cardioprotection is discussed, while recognizing that they are much more heterogeneous than other classes of antihypertensive or antianginal agents. Similarities and differences between the mechanisms of action and clinical effects of individual drugs are discussed. Among these is the ability of some of them to reduce left ventricular hypertrophy rapidly while simultaneously and uniquely increasing right ventricular wall thickness. Although the clinical importance of this as a potential cardioprotective effect is undetermined, the renal protective effect of some calcium antagonists is discussed in detail.

Calcium Channel Blockers

Comparative cytoprotective effect of dihydropyridine calcium channel blockers against the toxicity of oxidized low density lipoprotein for cultured lymphoid cells.

The ability of dihydropyridine Ca2+ channel blockers (nicardipine, nimodipine and nisoldipine) to inhibit low density lipoprotein (LDL) oxidation and to prevent the cytotoxicity of oxidized LDL for lymphoid cells have been compared. The lipid peroxidation of LDL promoted either by UV radiation or by copper ions was inhibited (antioxidant effect) in a dose-dependent manner by nisoldipine (IC50 values were evaluated at around 10 microM), whereas nimodipine was less potent (IC50 around 50-100 microM) and nicardipine almost inactive. The cytotoxicity of LDL treated (by UV or by copper) in the presence of effective antioxidant concentrations of dihydropyridine Ca2+ channel blockers was less than that of unprotected oxidized LDL (i.e. LDL oxidized in the absence of any dihydropyridine Ca2+ channel blockers). The inhibition of the cytotoxic effect of LDL oxidized in the presence of dihydropyridine Ca2+ channel blockers correlated well with protection from oxidation by these compounds. Beside this indirect protective effect, dihydropyridine Ca2+ channel blockers exhibit a direct protective effect for cells against the toxicity of previously oxidized LDL. Although complete protection cannot be obtained because of the cytotoxicity of the dihydropyridine compounds per se, the IC50 values were 6 +/- 2 and 80 +/- 20 microM for nisoldipine and nimodipine, respectively. The potential relevance to the prevention of atherogenesis is discussed.

Calcium Channel Blockers

Molecular and cellular aspects of calcium channel antagonism.

Calcium fluxes play a key role in controlling many physiologic processes and responses in the body. The past few years have witnessed major advances in understanding of L-type calcium channels and their blockade with calcium channel antagonists. The L-type calcium channels comprise 5 subunits termed alpha 1, alpha 2, beta, gamma, and delta. Elucidation of the mechanisms of action of the calcium channel antagonists has been advanced by cloning and genetic manipulation of these subunits. The alpha 1 subunit appears to be responsible for channel opening and voltage dependency, and it contains receptors for calcium channel antagonists; these geographically distinct receptors correspond to each of the 3 different chemical classes of antagonists, exemplified by diltiazem, nifedipine, and verapamil. Diltiazem appears to have an inhibitory effect on mitochondrial sodium-calcium exchange that is unique among calcium channel antagonists. Preliminary data suggest that a diltiazem-specific receptor also exists in the endothelium. It appears, therefore, that despite advances in the understanding of L-type calcium channels, much remains to be learned about other possible receptors for the calcium channel antagonists.

Calcium Channel Blockers